Primary Pleural Squamous Cell Carcinoma, Highly Positive PD-L1, Shows Marked Response to Camrelizumab: A Case Report

Here, we reported the rare case of primary pleural squamous cell carcinoma (PPSCC) in a 71-year-old male patient. After chemo and targeted therapies, the patient showed continuous tumor progression and clinical deterioration. Fortunately, the patient had a high expression level of PD-L1 (80%) in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yao, Gao, Ying, Chen, Hai-Ruo, Liu, Hong, Fu, Xi, Yan, Ran, You, Feng-Ming, Li, Zhuo-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278452/
https://www.ncbi.nlm.nih.gov/pubmed/34290540
http://dx.doi.org/10.1177/11795549211028571
_version_ 1783722263272488960
author Wang, Yao
Gao, Ying
Chen, Hai-Ruo
Liu, Hong
Fu, Xi
Yan, Ran
You, Feng-Ming
Li, Zhuo-Hong
author_facet Wang, Yao
Gao, Ying
Chen, Hai-Ruo
Liu, Hong
Fu, Xi
Yan, Ran
You, Feng-Ming
Li, Zhuo-Hong
author_sort Wang, Yao
collection PubMed
description Here, we reported the rare case of primary pleural squamous cell carcinoma (PPSCC) in a 71-year-old male patient. After chemo and targeted therapies, the patient showed continuous tumor progression and clinical deterioration. Fortunately, the patient had a high expression level of PD-L1 (80%) in the tumor tissues. Ultimately, the patient survived for additional 6 months with camrelizumab treatment. In summary, camrelizumab may be a good candidate for the treatment of PPSCC, especially in tumors with high PD-L1 expression.
format Online
Article
Text
id pubmed-8278452
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-82784522021-07-20 Primary Pleural Squamous Cell Carcinoma, Highly Positive PD-L1, Shows Marked Response to Camrelizumab: A Case Report Wang, Yao Gao, Ying Chen, Hai-Ruo Liu, Hong Fu, Xi Yan, Ran You, Feng-Ming Li, Zhuo-Hong Clin Med Insights Oncol Case Report Here, we reported the rare case of primary pleural squamous cell carcinoma (PPSCC) in a 71-year-old male patient. After chemo and targeted therapies, the patient showed continuous tumor progression and clinical deterioration. Fortunately, the patient had a high expression level of PD-L1 (80%) in the tumor tissues. Ultimately, the patient survived for additional 6 months with camrelizumab treatment. In summary, camrelizumab may be a good candidate for the treatment of PPSCC, especially in tumors with high PD-L1 expression. SAGE Publications 2021-07-12 /pmc/articles/PMC8278452/ /pubmed/34290540 http://dx.doi.org/10.1177/11795549211028571 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Wang, Yao
Gao, Ying
Chen, Hai-Ruo
Liu, Hong
Fu, Xi
Yan, Ran
You, Feng-Ming
Li, Zhuo-Hong
Primary Pleural Squamous Cell Carcinoma, Highly Positive PD-L1, Shows Marked Response to Camrelizumab: A Case Report
title Primary Pleural Squamous Cell Carcinoma, Highly Positive PD-L1, Shows Marked Response to Camrelizumab: A Case Report
title_full Primary Pleural Squamous Cell Carcinoma, Highly Positive PD-L1, Shows Marked Response to Camrelizumab: A Case Report
title_fullStr Primary Pleural Squamous Cell Carcinoma, Highly Positive PD-L1, Shows Marked Response to Camrelizumab: A Case Report
title_full_unstemmed Primary Pleural Squamous Cell Carcinoma, Highly Positive PD-L1, Shows Marked Response to Camrelizumab: A Case Report
title_short Primary Pleural Squamous Cell Carcinoma, Highly Positive PD-L1, Shows Marked Response to Camrelizumab: A Case Report
title_sort primary pleural squamous cell carcinoma, highly positive pd-l1, shows marked response to camrelizumab: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278452/
https://www.ncbi.nlm.nih.gov/pubmed/34290540
http://dx.doi.org/10.1177/11795549211028571
work_keys_str_mv AT wangyao primarypleuralsquamouscellcarcinomahighlypositivepdl1showsmarkedresponsetocamrelizumabacasereport
AT gaoying primarypleuralsquamouscellcarcinomahighlypositivepdl1showsmarkedresponsetocamrelizumabacasereport
AT chenhairuo primarypleuralsquamouscellcarcinomahighlypositivepdl1showsmarkedresponsetocamrelizumabacasereport
AT liuhong primarypleuralsquamouscellcarcinomahighlypositivepdl1showsmarkedresponsetocamrelizumabacasereport
AT fuxi primarypleuralsquamouscellcarcinomahighlypositivepdl1showsmarkedresponsetocamrelizumabacasereport
AT yanran primarypleuralsquamouscellcarcinomahighlypositivepdl1showsmarkedresponsetocamrelizumabacasereport
AT youfengming primarypleuralsquamouscellcarcinomahighlypositivepdl1showsmarkedresponsetocamrelizumabacasereport
AT lizhuohong primarypleuralsquamouscellcarcinomahighlypositivepdl1showsmarkedresponsetocamrelizumabacasereport

Ejemplares similares